Skip to main content
. 2020 Jan 13;2020(1):CD012643. doi: 10.1002/14651858.CD012643.pub3

Fiore 2010.

Notes Title: Early interim FDG‐PET during intensified BEACOPP therapy for advanced‐stage Hodgkin disease shows a lower positive predictive value than during ABVD.
(Conference abstract)
Aim

  • To examine the predictive role on treatment outcome of early interim FDG‐PET in individuals with HL, treated with BEACOPP (4 escalated + 4 baseline cycles)


Study design

  • Retrospective


Country/treatment centre(s)

  • Italy (8 haematological institutions)


Number of included participants

  • 44


Inclusion criteria

  • Diagnosed HL, advanced stage (IIB to IVB, or IIA with adverse prognostic factors)


Exclusion criteria

  • Not reported


Treatment

  • BEACOPP


Primary outcome measure(s)

  • Complete remission

  • Failure‐free survival